Previous 10 | Next 10 |
BOSTON, May 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Presid...
Rhythm Pharmaceuticals (RYTM): Q1 GAAP EPS of $0.90.Revenue of $0.04M.Rhythm expects that its existing cash, cash equivalents and short-term investments as of March 31, 2021, will be sufficient to fund its operating expenses and capital expenditure requirements into at least the second half o...
-- First U.S. commercial sales of IMCIVREE™ (setmelanotide) completed late in first quarter – -- Late-breaking data presentations at ENDO 2021 demonstrated continued weight loss with setmelanotide at up to nine months in HET obesity, as well as weight loss data in ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Insiders are people who have access to private information about a company and can do something called insider buying . They include a company’s senior management, members of the board of directors and other importa...
BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Ex...
Gainers: [[GTAT]] +49%. [[PFIN]] +13.6%. [[RYTM]] +5.6%. [[WING]] +3.8%. [[CLNE]] +3.1%.Losers: [[DISCB]] -10.9%. [[WMG]] -8.9%. [[TLS]] -7.7%. [[TXG]] -7.1%. [[BCEL]] -6.9%. For further details see: GTAT, PFIN, DISCB and BCEL among after-hours movers
Rhythm Pharmaceuticals (RYTM), over the weekend, posted data from its mid and late stage studies of anti-obesity medication setmelanotide at the 103rd Annual Meeting and Expo of the Endocrine Society ((ENDO 2021)).The presentations included data from a Phase 2 study of setmelanotide...
-- Responders with HET obesity achieved mean weight loss of greater than 12 percent at nine months on setmelanotide therapy -- -- Additional poster presentations include Phase 3 data in Bardet-Biedl and Alström syndromes and analyses of adverse events in Phase 2 and Pha...
BOSTON, March 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that three late-breaking abstracts have been accepted ...
Rhythm Pharmaceuticals (RYTM): Q4 GAAP EPS of -$0.79.Cash, cash equivalents and short-term investments of $172.8M.Press Release For further details see: Rhythm Pharmaceuticals reports Q4 results
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...